ASAH1 and neoplasm: These data prompted us to hypothesize that neither ASAH1 nor STING activity were relevant in tumor progression and survival, but when patients were stratified according to both target positivity or negativity, we found that lower expression of ASAH1 was associated to higher survival in STING+ patients (Figure 8C, ASAH1-STING+ 87 months vs. ASAH1+STING+ 59 months; p = 0.0475).